Inventiva S.A./€IVA
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Inventiva S.A.
Inventiva S.A. is a clinical-stage biopharmaceutical company based in France, focused on developing oral small molecule therapies for the treatment of diseases with unmet medical needs, particularly in the areas of fibrosis, lysosomal storage disorders, and oncology. The company’s leading product candidate is lanifibranor, which is currently in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Founded in 2012, Inventiva leverages its proprietary technology platform to identify and develop innovative compounds. The company's research and development operations are concentrated in Daix, France. Inventiva’s competitive strength lies in its robust pipeline and strategic collaborations with partners in the pharmaceutical industry. Sources:
1. https://inventivapharma.com/en/
2. https://ir.inventivapharma.com/
3. https://www.wallstreet-online.de/nachricht/14672309-inventiva-reports-financial-results-quarter-ended-september-30-2021
Ticker
€IVA
Sector
Primary listing
PAR
Employees
84
Headquarters
Website
Inventiva S.A. Metrics
BasicAdvanced
€475M
-
-€3.53
0.75
-
Price and volume
Market cap
€475M
Beta
0.75
52-week high
€5.49
52-week low
€2.00
Average daily volume
5.7K
Financial strength
Current ratio
2.956
Quick ratio
2.486
Long term debt to equity
-1,428.499
Total debt to equity
-1,490.605
Interest coverage (TTM)
-4.32%
Profitability
EBITDA (TTM)
-95.927
Gross margin (TTM)
92.09%
Net profit margin (TTM)
-1,833.03%
Operating margin (TTM)
-584.43%
Effective tax rate (TTM)
0.10%
Revenue per employee (TTM)
€200,000
Management effectiveness
Return on assets (TTM)
-56.77%
Return on equity (TTM)
707.22%
Valuation
Price to revenue (TTM)
17.714
Price to book
-53.26
Price to tangible book (TTM)
-52.76
Price to free cash flow (TTM)
-3.287
Free cash flow yield (TTM)
-30.42%
Free cash flow per share (TTM)
-1.037
Growth
Revenue change (TTM)
-10.36%
Earnings per share change (TTM)
70.33%
3-year revenue growth (CAGR)
20.31%
3-year earnings per share growth (CAGR)
36.39%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Inventiva S.A. stock?
Inventiva S.A. (IVA) has a market cap of €475M as of October 31, 2025.
What is the P/E ratio for Inventiva S.A. stock?
The price to earnings (P/E) ratio for Inventiva S.A. (IVA) stock is 0 as of October 31, 2025.
Does Inventiva S.A. stock pay dividends?
No, Inventiva S.A. (IVA) stock does not pay dividends to its shareholders as of October 31, 2025.
When is the next Inventiva S.A. dividend payment date?
Inventiva S.A. (IVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Inventiva S.A.?
Inventiva S.A. (IVA) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.